-+ 0.00%
-+ 0.00%
-+ 0.00%

Madrigal wins three new US patents for MASH drug Rezdiffra, boosting IP protection

PUBT·07/13/2026 12:04:13
Listen to the news
Madrigal wins three new US patents for MASH drug Rezdiffra, boosting IP protection
  • Madrigal Pharmaceuticals received three new U.S. patents covering Rezdiffra (resmetirom), strengthening protection in F2/F3 MASH through 2045.
  • Two patents will be listed in the FDA Orange Book, including dosing with moderate CYP2C8 inhibitors through 2045.
  • A separate Orange Book-listed patent covers co-administration with rosuvastatin, capping rosuvastatin at 20 mg/day, through 2042.
  • A third patent covers resmetirom use in well-compensated cirrhosis (F4c), extending protection through 2042.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Madrigal Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607130800PRIMZONEFULLFEED9760449) on July 13, 2026, and is solely responsible for the information contained therein.